We Offer Worldwide Shipping
Login Wishlist

Vasicinolone

$1,152

  • Brand : BIOFRON

  • Catalogue Number : BN-O1444

  • Specification : 98%(HPLC)

  • CAS number : 84847-50-7

  • Formula : C11H10N2O3

  • Molecular Weight : 218.2

  • PUBCHEM ID : 158720

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1444

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

218.2

Appearance

Powder

Botanical Source

This product is isolated and purified from the leaves of Adhatoda vasica

Structure Type

Alkaloids

Category

Standards;Natural Pytochemical;API

SMILES

C1CN2C(=NC3=C(C2=O)C=C(C=C3)O)C1O

Synonyms

Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3,7-dihydroxy-, (3S)-/Pyrrolo(2,1-b)quinazolin-9(1H)-one, 2,3-dihydro-3,7-dihydroxy-, (3S)-/(3S)-3,7-Dihydroxy-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-one

IUPAC Name

(3S)-3,7-dihydroxy-2,3-dihydro-1H-pyrrolo[2,1-b]quinazolin-9-one

Density

1.7±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

260.3±32.9 °C

Boiling Point

506.8±60.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C11H10N2O3/c14-6-1-2-8-7(5-6)11(16)13-4-3-9(15)10(13)12-8/h1-2,5,9,14-15H,3-4H2/t9-/m0/s1

InChl Key

MKNHUAILAQZBTQ-VIFPVBQESA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:84847-50-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29156688

Abstract

Background
Raising T-cell response against antigens either expressed on normal and malignant plasma cells (e.g. HM1.24) or aberrantly on myeloma cells only (e.g. cancer testis antigens, CTA) by vaccination is a potential treatment approach for multiple myeloma.

Results
Expression by GEP is found for HM1.24 in all, HMMR in 318/458 (69.4%), MAGE-A3 in 209/458 (45.6%), NY-ESO-1/2 in 40/458 (8.7%), and WT-1 in 4/458 (0.8%) of samples with the pattern being confirmed by RNA-sequencing. T-cell-activation is found in 9/26 (34.6%) of patient samples, i.e. against HM1.24 (4/24), RHAMM-R3 (3/26), RHAMM1-8 (2/14), WT-1 (1/11), NY-ESO-1/2 (1/9), and MAGE-A3 (2/8). In 7/19 T-cell activation responses, myeloma cells lack respective antigen-expression. Expression of MAGE-A3, HMMR and NY-ESO-1/2 is associated with adverse survival.

Experimental design
We assessed expression of HM1.24 and the CTAs MAGE-A3, NY-ESO-1/2, WT-1 and HMMR in CD138-purified myeloma cell samples of previously untreated myeloma patients in the GMMG-MM5 multicenter-trial by gene expression profiling (GEP; n = 458) and RNA-sequencing (n = 152) as potential population regarding vaccination trials. We then validated the feasibility to generate T-cell responses (n = 72) against these antigens by IFN-γ EliSpot-assay (n = 26) related to antigen expression (n = 22). Lastly, we assessed survival impact of antigen expression in an independent cohort of 247 patients treated by high-dose therapy and autologous stem cell transplantation.

Conclusions
As T-cell responses can only be raised in a subfraction of patients despite antigen expression, and the number of responses increases with more antigens used, vaccination strategies should assess patients’ antigen expression and use a “cocktail” of peptide vaccines.

KEYWORDS

tumor associated antigens, T cells, immunogenicity, multiple myeloma, RNA-sequencing

Title

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial

Author

Michael Schmitt,1,* Angela G. Huckelhoven,1,* Michael Hundemer,1 Anita Schmitt,1 Susanne Lipp,1 Martina Emde,1 Hans Salwender,2 Mathias Hanel,3 Katja Weisel,4 Uta Bertsch,1 Jan Durig,5 Anthony D. Ho,1 Igor Wolfgang Blau,6 Hartmut Goldschmidt,1,7 Anja Seckinger,1 and Dirk Hose1

Publish date

2017 Oct 17;

PMID

16336197

Abstract

The cAMP signalling pathway has emerged as a key regulator of haematopoietic cell proliferation, differentiation and apoptosis. In parallel, general understanding of the biology of cyclic nucleotide PDEs (phosphodiesterases) has advanced considerably, revealing the remarkable complexity of this enzyme system that regulates the amplitude, kinetics and location of intracellular cAMP-mediated signalling. The development of therapeutic inhibitors of specific PDE gene families has resulted in a growing appreciation of the potential therapeutic application of PDE inhibitors to the treatment of immune-mediated illnesses and haematopoietic malignancies. This review summarizes the expression and function of PDEs in normal haematopoietic cells and the evidence that family-specific inhibitors will be therapeutically useful in myeloid and lymphoid malignancies.

KEYWORDS

cAMP, cancer therapy, glucocorticoid, leukaemia, methylxanthine, phosphodiesterase

Title

Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies

Author

Adam Lerner*† and Paul M. Epstein‡,1

Publish date

2006 Jan 1;

PMID

28103794

Abstract

Background
Staphylococcus aureus (Staph. aureus) is one of the major pathogens causing mastitis in dairy ruminants worldwide. The chronic nature of Staph. aureus infection enhances the contagiousness risk and diffusion in herds. In order to identify the factors involved in intra-mammary infection (IMI) and diffusion in dairy cows, we investigated the molecular characteristics of two groups of Staph. aureus strains belonging to ST8 and ST398, differing in clinical properties, through comparison of whole genome and whole transcriptome sequencing.

Results
The two groups of strains, one originated from high IMI prevalence herds and the other from low IMI prevalence herds, present a peculiar set of genes and polymorphisms related to phenotypic features, such as bacterial invasion of mammary epithelial cells and host adaptation. Transcriptomic analysis supports the high propensity of ST8 strain to chronicity of infection and to a higher potential cytotoxicity.

Conclusions
Our data are consistent with the invasiveness and host adaptation feature for the strains GTB/ST8 associated to high within-herd prevalence of mastitis. Variation in genes coding for surface exposed proteins and those associated to virulence and defence could constitute good targets for further research.

Electronic supplementary material
The online version of this article (doi:10.1186/s12866-017-0931-8) contains supplementary material, which is available to authorized users.

KEYWORDS

Staphylococcus aureus, Mastitis, Virulence, Genome, Transcriptome, Next generation sequencing

Title

Genomic and transcriptomic comparison between Staphylococcus aureus strains associated with high and low within herd prevalence of intra-mammary infection

Author

E. Capra,corresponding author#1 P. Cremonesi,#1 A. Pietrelli,2,6 S. Puccio,2,5 M. Luini,3 A. Stella,1,4 and B. Castiglioni1

Publish date

2017;


Description :

Empty ...